Home > ECTRIMS 2017 – Kumaran Deiva Interview
Multiple Sclerosis, Paediatric Neurology

ECTRIMS 2017 – Kumaran Deiva Interview

Published Online: November 3rd 2017

Kumaran Deiva shares his insights and highlights on paediatric MS from ECTRIMS-ACTRIMS 2017.

1. What have been the most significant recent developments in paediatric MS? (0:05)
2. Discuss the current unmet needs and/or the challenges you face as a paediatric MS specialist (0:38)
3. What are the most promising areas of paediatric MS research? (01:33)
4. Which presentations/data at ECTRIMS-ACTRIMS have interested you the most? (02:15)
5. Do you have a message for young paediatric MS specialists in Europe/US? (02:47)

Speaker disclosures: Kumaran Deiva has nothing to disclose in relation to this video interview.

Filmed at the 7th Joint ECTRIMS-ACTRIMS Meeting, Paris, France, October 2017.

Share this Video
Related Videos In Paediatric Neurology
Epilepsy, Paediatric Neurology
Ingrid Scheffer, AES 2020 – Long Term Efficacy and Safety of Fenfluramine in Patients with Dravet Syndrome

We were delighted to talk to Ingrid Scheffer (The University of Melbourne, The Royal Children’s Hospital and Austin Health, Victoria, Australia) regarding the open-label extension study of fenfluramine in patients with Dravet syndrome (Clinical Trial Identifier: NCT02823145). The abstract ‘Efficacy and Tolerability of Adjunctive FINTEPLA (Fenfluramine Hydrochloride) in an Open-Label Extension Study of Dravet Syndrome […]

Epilepsy, Paediatric Neurology
Kelly Knupp, AES 2020 – Fenfluramine for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome

We caught up with Kelly Knupp (University of Colorado, Anschutz Medical Campus, Children’s Hospital Colorado, CO, USA) to discuss the use of fenfluramine for the reduction of seizures associated with Lennox-Gastaut syndrome. (Clinical Trial Identifier: NCT03355209). The abstract ‘Efficacy and safety of FINTEPLA (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized, […]

COVID-19, Epilepsy, Paediatric Neurology
DSUK – Dravet Syndrome in the COVID-19 Pandemic – Webinar with Professor Helen Cross OBE

Video produced by and shared with kind authorisation of Dravet Syndrome UK (DSUK). Professor Helen Cross OBE is a globally-recognised authority on Dravet Syndrome and Chair of DSUK’s Medical Advisory Board. On Monday 30 March, she took part in a webinar for families registered with DSUK, presenting on COVID-19 and answering a range of questions. […]

Trending In Paediatric Neurology:

Ingrid Scheffer, AES 2020 – Long Term Efficacy and Safety of Fenfluramine in Patients with Dravet Syndrome
Epilepsy, Paediatric Neurology
    • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72